Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206635 · ClinicalTrials.gov registry record
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 432
- Enrollment target
NCT00206635: Completed study, sponsored by Bayer.
NCT00206635 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 432 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206635 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 432 participants
- Enrollment target
Study Summary
The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
Interventions
- DRUG Interferon beta-1b (Betaseron, BAY86-5046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
What the finished NCT00206635 record still lists
NCT00206635 is an observational study that tracks outcomes without assigning an intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Interferon beta-1b (Betaseron, BAY86-5046) is the first listed.
NCT00206635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206635 about?
NCT00206635 is a clinical study titled "Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis". The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
What is the current status of trial NCT00206635?
This trial is currently completed. The enrollment target is 432 participants. The study started on 2005-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00206635?
The interventions under investigation include: Interferon beta-1b (Betaseron, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00206635?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia